



December 18, 2018

Ms. April Samuels
Breast Cancer Can Stick It! Foundation

Dear April,

On behalf of Baylor Health Care System Foundation, it's my privilege to update you on the progress of the breast cancer research at Baylor Scott & White, which has been generously supported by Breast Cancer Can Stick It! Foundation.

SELKIRK VACCINE TRIAL

As you know, Dr. Joyce O'Shaughnessy has tirelessly led research efforts targeted at finding better therapies and treatments for triple negative breast cancer. Her trial that was initially funded by your foundation evaluated if a vaccine using a patient's own dendritic cells would be effective against a deadly form of triple-negative breast cancer (TNBC) that is unresponsive to standard therapies.

The trial completed enrollment of 10 patients with TNBC. Each patient received four doses of the vaccine during preoperative chemotherapy, and eight of the 10 patients received all seven vaccine doses. The vaccine administration proved safe, yielding no more adverse effects than if the patients had been treated with chemotherapy alone.

The potential value of the vaccine will not be fully determined until every patient has completed their three-year enrollment in early 2019. If the surviving patients continue to remain disease free by the conclusion of the trial, it may suggest that a new viable treatment for TNBC may have been found.

Dr. O'Shaughnessy and her team presented their preliminary findings on this study at the American Society of Clinical Oncology (ASCO) annual meeting in June 2016. This exposed this trial to the world's leading oncologists.

BORTEZOMIB TRIAL

Another TNBC research trial that Dr. O'Shaughnessy is currently working on was inspired by a patient who participated in a previous trial for a potential cancer drug called BEZ 235. This special patient, "Jane Doe," had six recurrences of TNBC despite five years of surgeries, chemotherapy, radiation, genomic sequencing and personalized treatment.

When she met with Dr. O'Shaughnessy, Jane had few remaining options she had not already tried. So, Dr. O'Shaughnessy began treating Jane with a new chemotherapy regimen, and something amazing happened. Jane had what is called a durable complete response and has now been cancer free for more than five years.

Dr. O'Shaughnessy hypothesized that, although the BEZ-235 Jane took in her clinical trial did not cure her cancer, the drug sensitized her cancer cells and primed them to be vulnerable to the chemotherapy.

Since the trial using BEZ-235 has been discontinued, Dr. O'Shaughnessy set out to find a drug with similar mechanisms that would impact cancer cells in the same way. The drug she identified, Bortezomib, is FDA-approved and already used for treatment of multiple myeloma.

Dr. O'Shaughnessy is now raising money to launch a clinical trial to determine if this new TNBC treatment will prove effective for others like it did for Jane. This trial will expand the options available to patients with metastatic disease, expedite the timeline for enrollment, and bring hope quickly to those in need.

With each step, we are learning more about this insidious disease. Please know how grateful we all are for your support in this effort. We are proud of what is being accomplished today and look forward to what will be achieved in the days and years ahead for breast cancer patients throughout the world.

April, your foundation's support has helped make all of this work possible.

Sincerely,

A handwritten signature in blue ink, appearing to read "Sarah", written in a cursive style.

Sarah H. Burdi, CFRE
Director